Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 10/07/2025 BST			5-day change	1st Jan Change
9.010 ^USD	-3.63%		-1.96%	-60.44%

07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
07-08	Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	CI

Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 13/05/2025 at 21:04

Quoin Pharmaceuticals, Ltd. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 3.81 million compared to USD 2.33 million a year ago.

Latest news about Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	07-08	RE
Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	07-08	CI
Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	06-26	CI
Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	CI
Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain Options of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain American Depositary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain Ordinary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	05-22	CI
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	RE
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	05-22	MT
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing	05-14	MT
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Quoin Pharmaceuticals Regains Compliance With Nasdaq	04-30	RE
Quoin Pharmaceuticals Changes ADS Ratio to Meet Nasdaq Rule	04-04	MT
Quoin Pharmaceuticals - Subject's Skin Almost Completely Healed After 6 Weeks Of Qrx003	04-02	RE
Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	04-02	CI
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	03-25	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-13	CI
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	03-04	CI
Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study	02-27	CI
Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	01-23	CI
Quoin Pharmaceuticals Ltd. Announces Positive Clinical Data from its Ongoing Pediatric Netherton Syndrome Study	01-16	CI
Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	01-06	CI

Chart Quoin Pharmaceuticals, Ltd.

Duration

Period

QNRX: Dynamic Chart

Company Profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-13 - Q2 2025 Earnings Release (Projected)

More about the company